⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
DSGN News
Design Therapeutics, Inc. Common Stock
Diagonal Therapeutics Announces First Patient Dosed in Phase 1/2 DIAMOND Clinical Trial of DIAG723 for Hereditary Hemorrhagic Telangiectasia (HHT)
globenewswire.com
DSGN
Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1
globenewswire.com
DSGN
Form 8-K
sec.gov
DSGN
Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
globenewswire.com
DSGN
BlossomHill Therapeutics Expands Board of Directors with the Appointments of Sheila Gujrathi, M.D., and John Schmid
globenewswire.com
ANAB
DSGN
Form 8-K
sec.gov
DSGN
Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia
globenewswire.com
DSGN
Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026
globenewswire.com
DSGN
Form 8-K
sec.gov
DSGN
Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates
globenewswire.com
DSGN